Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off - 26 U.S. States for Climbing
- 3As nations push for more ambition at climate talks, chairman says they may get it
- 4Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- 57 Well known Vacation spots In The US
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- Find the Future of Outsourcing: Exploring the Gig Economy
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Zelensky warns of imminent massive Russian attack on Ukraine
- Figure out How to Recognize Early Indications of Depressions
- Manual for Famous Beverages 2024
- Saturn shines with the waxing moon at sunset on Nov. 29
